pdufa.bio
Home › Decisions › SPRO 2026-06-17

SPRO FDA decision — Jun 17, 2026

✓ APPROVED

Spero Therapeutics Inc. — Utebzi (Tebipenem HBr) - (PIVOT-PO) · Complicated urinary tract infection (cUTI), includ.

Run-up into the decision (T-120 → T+5)

PDUFA 6/17/26$2.98$2.1412/31/25
Daily close, T-120 (12/31/25) through T+5. Run-up high $2.98 on 6/4/26, low $2.14 on 2/6/26 (T-120 to T-1). FDA decision 6/17/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-17
OutcomeApproved
Drug / candidateUtebzi (Tebipenem HBr) - (PIVOT-PO)
CompanySpero Therapeutics Inc.
120-day run-up (T-120→T-1)+18.9%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio